Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Synthetic peptide hydrogel-based human in vitro corneal model
Author Affiliations & Notes
  • Dovile Litvinaviciute
    R&D, Experimentica Ltd, Vilnius, Lithuania
  • Justina Urbanaviciute
    R&D, Experimentica Ltd, Vilnius, Lithuania
  • Tadas Jelinskas
    Ferentis, Vilnius, Lithuania
  • Airina Mazetyte-Godiene
    Ferentis, Vilnius, Lithuania
  • Vytautas Cepla
    Ferentis, Vilnius, Lithuania
  • Ruta Aldonyte
    Ferentis, Vilnius, Lithuania
  • Jenni J. Hakkarainen
    R&D, Experimentica Ltd, Kuopio, Finland
  • Footnotes
    Commercial Relationships   Dovile Litvinaviciute None; Justina Urbanaviciute None; Tadas Jelinskas None; Airina Mazetyte-Godiene None; Vytautas Cepla None; Ruta Aldonyte None; Jenni Hakkarainen Experimentica Ltd., Code I (Personal Financial Interest)
  • Footnotes
    Support  EU fund 01.2.1-LVPA-K-856-01-0210 (BioCornea)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4476. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dovile Litvinaviciute, Justina Urbanaviciute, Tadas Jelinskas, Airina Mazetyte-Godiene, Vytautas Cepla, Ruta Aldonyte, Jenni J. Hakkarainen; Synthetic peptide hydrogel-based human in vitro corneal model. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4476.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Synthetic peptide hydrogels are promising scaffolds where cornea epithelium and other cell types can be grown into in vitro cultures. The aim of this study was to develop a corneal model employing a peptide hydrogel layer as a mimetic of corneal stroma. The model was used in the assessment of corneal cytotoxicity and penetration properties of prostaglandin analogs that are considered as first-line treatment for glaucoma.

Methods : The hydrogel was produced from human collagen-mimetic peptides exhibiting relevant properties. The hydrogels were cast into microplate wells and cell culture inserts. Human corneal epithelial cells (HCE-T) were seeded on the hydrogels and multilayered for the permeability experiments using the air-liquid interface method. In the cell viability experiments, the plastic-based conventional microplate cultures were used as a control condition. Cytotoxicity of benzalkonium chloride (BAK) and prostaglandin analogs, bimatoprost, latanoprost, tafluprost and travoprost (50 mM), were assessed using PrestoBlue and lactate dehydrogenase release assays. The permeability of fluorescent reference molecules, i.e., FITC-dextran 70 kDa and 4 kDa, Rhodamine 123, 6-carboxyfluorescein and Rhodamine B, and prostaglandin analogs was measured.

Results : There was a clear dose-response in the cytotoxicity at clinically relevant BAK concentrations. The IC50 values of BAK in HCE-T cells grown in plastic microplates were slightly lower (0.0056%) than on hydrogels (0.0079%). Latanoprost, tafluprost, travoprost and positive control BAK (0.01%) significantly decreased the cell viability on microplates (P<0.0001) and on hydrogels (P<0.05 latanoprost, P<0.01 tafluprost, P<0.01 travoprost, P<0.0001 BAK). Nevertheless, the cell viability was maintained relatively high (>72% on microplates, >86% on hydrogels) with all tested prostaglandin analogs. The apparent permeability coefficient (Papp) values between prostaglandin analogs were different. Tafluprost and travoprost showed very low Papp values. On the contrary, latanoprost and bimatoprost were identified as high permeability molecules with high Papp values.

Conclusions : We provide evidence that the HCE-T cells grown on human collagen-mimetic peptide hydrogels that mimic the stroma is suitable as a corneal in vitro model. The model is convenient for the assessment of cytotoxicity and permeability of ophthalmic drugs in the preclinical phase of drug development

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×